KZIA ▲ +1.1% - Kazia Therapeutics Limited $KZIA KZIA KZIA - Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer Kazia Therapeutics rose 1.1% following the release of positive clinical trial data showing a 100% clinical benefit rate among the first six patients treated for advanced triple-negative breast cancer. The strong early efficacy results in this treatment-resistant cancer type likely drove investor optimism about the company's therapeutic candidate. This initial data suggests potential promise for addressing a serious unmet medical need in oncology. 27-AUG-2026 04:02 PM ET